Prim Care Companion CNS Disord. 2026 Mar 10;28(2):25m04074. doi: 10.4088/PCC.25m04074.
ABSTRACT
Objective: To evaluate if ultra-low-dose mirtazapine (3.75 mg) improves insomnia without next-day effects.
Methods: This retrospective study evaluated data collected from September 5, 2024, to March 7, 2025, from an outpatient setting consisting of veterans with insomnia who were treated with ultra-low-dose mirtazapine. The Insomnia Severity Index (ISI) was administered during the first appointment and at each subsequent visit with the respective psychiatrist to monitor insomnia symptoms. Summary statistics were used to compare ISI scores at baseline and 1-3 months after starting treatment.
Results: Considering all veterans evaluated (N = 53), 47% showed a meaningful decrease in ISI value (greater than 7 points). Patients who completed treatment showed a constant or decreased ISI score (mean [SD] change: 11.3 [6.46]).
Conclusion: Ultra-low-dose mirtazapine may improve symptoms and ISI values for chronic insomnia.
Prim Care Companion CNS Disord 2026;28(2):25m04074.
Author affiliations are listed at the end of this article.
PMID:41861363 | DOI:10.4088/PCC.25m04074
